Matinas BioPharma Holdings, Inc. - MTNB STOCK NEWS

Matinas BioPharma Holdings (MTNB) reported fourth quarter and full year 2021 results, highlighting a net loss of $6.7 million for Q4 and $23.7 million for the year. Enrollment in the EnACT trial's fourth cohort continues, with 15 patients enrolled so far, and topline data expected in Q3 2022. The company plans to expand the trial into a fifth cohort pending FDA approval. They ended 2021 with $49.6 million in cash, sufficient to fund operations into 2023. A new in vivo study for LNC-remdesivir will begin in March 2022, aiming for further advancements in nucleic acid delivery technology.

Matinas BioPharma Holdings (MTNB) will host a conference call on March 8, 2022, at 8:30 a.m. ET to discuss its Q4 and full-year 2021 financial results. Interested participants can call (877) 407-5976 (Toll-Free) or (412) 902-0031 (Toll) and use conference ID 13727084. The live audio webcast will be available on Matinas' website, with an archive lasting 90 days. The company focuses on its lipid nanocrystal (LNC) platform technology, aiming to enhance intracellular delivery of drugs, including MAT2203 and MAT2501, which target serious infections and diseases.

Matinas BioPharma (MTNB) recently announced a successful End of Phase 2 meeting with the FDA regarding its MAT2203 program, which aims to treat invasive fungal infections. The company reported a survival rate of 98% in patients using MAT2203 compared to 88% with standard treatments. MAT2203's NDA submission is anticipated for late 2023, pending additional data from an expanded clinical trial. Financially, Matinas ended 2021 with approximately $49.9 million, sufficient to support operations through 2023. Collaborations with NIAID and Genentech remain promising for continued development.

Matinas BioPharma Holdings, Inc. (NYSE: MTNB) will host a conference call and audio webcast on January 25, 2022, at 8:30 a.m. ET to discuss corporate updates and its 2022 business outlook. The call will include updates on ongoing programs and collaborations. Key product candidates include MAT2203, an oral formulation of amphotericin B in a Phase 2 study for cryptococcal meningitis, and MAT2501, in Phase 1 for NTM lung disease. LYPDISO™, an omega-3 therapy, is also under development. The call can be accessed via their website.

Matinas BioPharma Holdings, Inc. (MTNB) reported that the Data and Safety Monitoring Board (DSMB) has approved the progression to the fourth cohort of the EnACT trial, evaluating MAT2203 for cryptococcal meningitis. The third cohort demonstrated successful antifungal activity above the target threshold, maintaining a strong safety profile. Enrollment for 40 additional patients is anticipated to start in early Q1 2022. MAT2203 aims to be a first-line treatment option, potentially transforming the landscape for invasive fungal infections.

Matinas BioPharma Holdings, Inc. (NYSE: MTNB) has appointed Thomas Hoover as the Chief Business Officer, focusing on business and corporate development. Hoover brings nearly 20 years of biopharmaceutical experience, including previous roles at Millendo Therapeutics and Sunovion. CEO Jerome D. Jabbour expressed confidence in Hoover's ability to advance the company's lipid nanocrystal (LNC) platform during this critical period. Matinas is developing multiple LNC formulations, including MAT2203 for invasive fungal infections and MAT2501 for bacterial infections, and plans to partner further on its omega-3 therapy, LYPDISO.

Matinas BioPharma Holdings (NYSE: MTNB) has been invited to present at the Piper Sandler 33rd Annual Virtual Healthcare Conference from November 29 to December 2, 2021. The company will showcase its innovative lipid nanocrystal (LNC) delivery platform and will hold investor meetings. A pre-recorded presentation will be available on the company’s IR Calendar page starting November 22, 2021, at 10:00 a.m. ET. Additionally, CEO Jerome D. Jabbour will lead a fireside chat at the B. Riley Fall 2021 Growth Biotech Best Ideas Series on November 23, 2021, at 12:30 p.m. ET.

Matinas BioPharma Holdings (MTNB) reported positive results from the first two cohorts of its EnACT study for MAT2203, an oral treatment for cryptococcal meningitis, prompting the DSMB to recommend progressing in the study. Additionally, the company initiated a Phase 1 study for MAT2501, an oral aminoglycoside antibiotic. Financially, MTNB reported a net loss of $6.8 million for Q3 2021, consistent with the previous year. The company believes it has sufficient cash reserves of $53.8 million to fund operations into 2024. Kathryn Penkus Corzo joined the Board of Directors.

Matinas BioPharma Holdings (MTNB) will host a conference call on November 8, 2021, at 8:30 a.m. ET to discuss its Q3 2021 operational and financial results. To join, call (877) 407-5976 (toll-free) or (412) 902-0031 (toll), using conference ID 13723555. The call will also be webcast on their website, where it will be archived for 90 days. Matinas specializes in a lipid nanocrystal delivery platform for therapeutics, with ongoing studies for drug candidates MAT2203 and MAT2501, targeting fungal and bacterial infections respectively.